Association between PD-L1 expression and driver gene mutations in non-small cell lung cancer patients: correlation with clinical data

摘要: Lung cancer is the leading cause of death worldwide. Recently, promising therapies have emerged based on PD-1/PD-L1 immune checkpoint inhibitors, which been approved even as frontline treatment for patients with non-small cell lung (NSCLC). We examined association between PD-L1 expression and clinicopathological parameters well overall survival in 220 NSCLC patients. was estimated by immunohistochemistry using 22C3 PharmDx Dako assay defined high, if TPS ≥ 50%, low, 1%–49%, absent, < 1%. EGFR mutations were detected COBAS while KRAS BRAF pyrosequencing. ROS1 ALK rearrangements positive cases being confirmed CISH FISH, respectively. Data analysis performed SPSS v25.0. positively correlated mutations. Anti-PD-1 therapy (pembrolizumab) prolonged compared to any other treatment. This effect more pronounced KRAS-mutated wild-type ones. Patients – high or low who had treated pembrolizumab, showed significant benefit negative expressors did not receive immunotherapy. In multivariate analysis, status, stage pembrolizumab independent variables survival. (TPS ≥ 1%) itself a poor prognostic factor, may affect tumour microenvironment patient’s response Immune inhibitors could represent an alternative therapeutic option particularly Further investigation into this notion warranted order validate observation.